SHANGHAI, China and CUPERTINO, Calif., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today announced a scheduled presentation to release 48-week clinical data from the Phase IIb trial of its ReJoin® human adipose-derived mesenchymal progenitor cell (haMPC) therapy for Knee Osteoarthritis (KOA) at the 8th Annual BioTech Showcase investor conference to be held in San Francisco, CA January 11-13, 2016.
Conference: 8th Annual BioTech Showcase 2016
Date: Tuesday, January 12, 2016
Time: 10:00 AM PDT
Title: Alteration of Knee Osteoarthritis, ReJoin® Phase IIb One Year Follow Up Results
Location: Track C - Mission II, 4th Floor, Parc 55, Union Square, 55 Cyril Magnin Street, San Francisco, CA
Presenter: Wei (William) Cao, PhD, BM, Chief Executive Officer
Company management will attend the conference and be available for discussions. To arrange one-to-one meetings with management, please contact email@example.com. The presented data analysis will be available on the Company website following the presentation.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative and cancerous diseases. Our developmental stem cell and Immuno-Oncology projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility in China, consisting of six independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy, including the devaluation of the RMB by China in August 2015 and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
Contacts: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 firstname.lastname@example.org Vivian Chen Managing Director Investor Relations, Grayling +1 347 481-3711 email@example.com
Source:Cellular Biomedicine Group Inc.